Both in Pharmaceuticals
Cartesian Therapeutics vs Upstream Bio
Over the past year RNAC returned −30.4% and UPB returned −86.8%; their daily moves had a correlation of 0.16.
RNAC −30.4% UPB −86.8%Growth of $1, one year, split-adjusted
| Metric | RNAC | UPB |
|---|---|---|
| Price | $6.27 | $2.76 |
| Market cap | $189.7M | $151.2M |
| Today | −4.71% | −18.10% |
| 1 month | −20.2% | −48.0% |
| 6 months | −10.9% | −72.4% |
| Year to date | −13.0% | −89.8% |
| 1 year | −35.0% | −87.3% |
| Revenue growth (YoY) | −100.0% | −17.5% |
| Gross margin | — | 100.0% |
| Net margin | — | −5136.1% |
| P/E (TTM) | — | — |
| Price / sales | 128.4× | 47.9× |
| Net cash | $94.8M | $261.3M |
| Dividend yield | — | — |
| Volatility (60d) | 48.5% | 76.9% |
| Short % of float | 15.4% | 13.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).